Prevention of viral hepatitis in the Nordic countries and Germany

被引:9
作者
Fitzsimons, D
Francois, G
Alpers, K
Radun, D
Hallauer, J
Jilg, W
Gerlich, W
Rombo, L
Blystad, H
Nokleby, H
Van Damme, P
机构
[1] Univ Antwerp, Dept Epidemiol & Social Med, Viral Hepatitis Prevnet Board, WHO Collaborating Ctr Prevent & Control Viral Hep, BE-2610 Antwerp, Belgium
[2] WHO, CH-1211 Geneva, Switzerland
[3] Robert Koch Inst, Dept Infect Dis Epidemiol, Unit Gastrointestinal Infect Zoonoses & Trop Infe, D-1000 Berlin, Germany
[4] Robert Koch Inst, Dept Infect Dis Epidemiol, Unit HIV AIDS STI & Blood Borne Infect, D-1000 Berlin, Germany
[5] Univ Klinikum Charite, Gesundheitssyst Forsch, Berlin, Germany
[6] Univ Regensburg, Inst Med Mikrobiol & Hyg, D-8400 Regensburg, Germany
[7] Univ Giessen, Univ Klinikum, Inst Med Virol, Giessen, Germany
[8] Karolinska Inst, Stockholm, Sweden
[9] Malarsjukhuset, Dept Infect Dis, Eskilstuna, Sweden
[10] Norwegian Inst Publ Hlth, Div Infect Dis Control, Oslo, Norway
关键词
D O I
10.1080/00365540510043284
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The Viral Hepatitis Prevention Board (VHPB) convened a meeting of international experts from the public and private sectors in the Nordic countries and Germany, in order to review the epidemiological situation, the surveillance systems for infectious diseases, the immunization programmes and policy, and the monitoring of adverse events after hepatitis vaccination in those countries, to evaluate prevention and control measures, and to identify the issues that arose and the lessons learnt. Considerable progress has been made in the past decades in the prevention and control of viral hepatitis in the respective countries. Vaccination programmes have been set up, blood products' safety has significantly been improved, and outbreak investigations remain the basis for the implementation of control measures. However, additional work remains to be done. Awareness of viral hepatitis among the public and professionals should further be raised, and more political support is needed regarding the value of prevention efforts and vaccination programmes.
引用
收藏
页码:549 / 560
页数:12
相关论文
共 58 条
  • [1] A hepatitis B vaccine formulated with a novel adjuvant system
    Ambrosch, F
    Wiedermann, G
    Kundi, M
    Leroux-Roels, G
    Desombere, I
    Garcon, N
    Thiriart, C
    Slaoui, M
    Thoelen, S
    [J]. VACCINE, 2000, 18 (20) : 2095 - 2101
  • [2] Hepatitis C virus infection in injection drug users in Bavaria: Risk factors for seropositivity
    Markus Backmund
    Kirsten Meyer
    Martin Wächtler
    Dieter Eichenlaub
    [J]. European Journal of Epidemiology, 2003, 18 (6) : 563 - 568
  • [3] Immunization with an adjuvant hepatitis B vaccine after liver transplantation for hepatitis B-related disease
    Bienzle, U
    Günther, M
    Neuhaus, R
    Vandepapeliere, P
    Vollmar, J
    Lun, A
    Neuhaus, P
    [J]. HEPATOLOGY, 2003, 38 (04) : 811 - 819
  • [4] Hepatitis A immunity in the Swedish population - A study of the prevalence of markers in the Swedish population
    Bottiger, M
    Christenson, BC
    Grillner, L
    [J]. SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 1997, 29 (02) : 99 - 102
  • [5] Virus-inhibiting surgical glove to reduce the risk of infection by enveloped viruses
    Bricout, F
    Moraillon, A
    Sonntag, P
    Hoerner, P
    Blackwelder, W
    Plotkin, S
    [J]. JOURNAL OF MEDICAL VIROLOGY, 2003, 69 (04) : 538 - 545
  • [6] *BUND, 2000, GES VERH BEK INF KRA, P1045
  • [7] CHAMOT E, 1992, AIDS, V6, P430, DOI 10.1097/00002030-199204000-00013
  • [8] Outbreak of Hepatitis B among injecting drug users in Denmark
    Christensen, PB
    Krarup, HB
    Niesters, HGM
    Norder, H
    de Muckadell, OBS
    Jeune, B
    Georgsen, J
    [J]. JOURNAL OF CLINICAL VIROLOGY, 2001, 22 (01) : 133 - 141
  • [9] Cockcroft A, 2000, REV MED VIROL, V10, P79, DOI 10.1002/(SICI)1099-1654(200003/04)10:2&lt
  • [10] 79::AID-RMV274&gt